AlphAIalphai — Financial news for AI agents
StockNASDAQ · US · USDHealthcare · DIAGNOSTICS & RESEARCH

$IMDX

Insight Molecular Diagnostics Inc.

Price · $IMDXvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $IMDX in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $IMDX in the last 30 days.

Top stories · $IMDXMore →
JUN 21·finance.yahoo.comLow

Breakthrough Science Meets Market Skepticism: Insight Molecular Diagnostics Inc. (IMDX)’s Defining Moment

Insight Molecular Diagnostics (NASDAQ:IMDX) said new data published June 11 in the American Journal of Transplantation show its GraftAssure Combination Model (CM-score) correlates with kidney transplant rejection and distinguishes rejection from non-rejection cases. BTIG reiterated a Neutral rating on May 15, citing pending FDA approval of GraftAssureDx in a $2B+ market.

JUN 17·SEC EDGAR 8-K

Insight Molecular Diagnostics Inc. (IMDX): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Insight Molecular Diagnostics Inc. (IMDX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001642380 0001642380 2026-06-11 2026-06-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor

APR 28·Stock Titan

Broadwood and Neal Bradsher hold 39.7% of Insight Molecular (IMDX) shares

Broadwood Partners, Broadwood Capital, and Neal C. Bradsher have reported a combined beneficial ownership of 12,835,134 shares, or 39.7%, of Insight Molecular Diagnostics (IMDX). This stake is based on 32,318,071 outstanding shares, adjusted to include warrants they beneficially own. The filing indicates the group intends to continuously review their investment and may engage with company management and the board to explore strategic alternatives for enhancing shareholder value.

IMDX sentiment & insider activity

Recent IMDX coverage spans financial news, technology and corporate actions.

What's driving IMDX

  • Peer-reviewed clinical/diagnostic performance data strengthens the scientific case for IMDX’s transplant rejection monitoring assay ahead of FDA-related expectations.

    finance.yahoo.com · Jun 21, 2026

  • Board re-election and expanded equity authorization can affect dilution expectations and governance optics, but no operational or financial guidance is provided.

    SEC EDGAR 8-K · Jun 17, 2026

  • Major shareholders Broadwood Partners, Broadwood Capital, and Neal C. Bradsher have increased their stake in Insight Molecular Diagnostics (IMDX) to 39.7%, indicating a potential shift towards a more activist approach. This could lead to strategic changes, including possible management engagement or corporate restructuring.

    Stock Titan · Apr 28, 2026

  • IMDX demonstrates positive progress towards its 2026 commercial goals, with key milestones achieved, including FDA submission plans and expansion into new markets.

    Benzinga · Nov 10, 2025

  • The announcement of successful clinical results for IMDX's kidney transplant therapy and monitoring system is likely to have a positive impact on the company's stock, potentially leading to increased investor confidence and upward price movement in the short to medium term.

    GlobeNewswire · Oct 6, 2025

alphai scores every news story that mentions IMDX with an AI model for sentiment and relevance, and aggregates insider trades from Insight Molecular Diagnostics Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $IMDX

Score
JUN 21$IMDXLowfinance.yahoo.com

Breakthrough Science Meets Market Skepticism: Insight Molecular Diagnostics Inc. (IMDX)’s Defining Moment

Insight Molecular Diagnostics (NASDAQ:IMDX) said new data published June 11 in the American Journal of Transplantation show its GraftAssure Combination Model (CM-score) correlates with kidney transplant rejection and distinguishes rejection from non-rejection cases. BTIG reiterated a Neutral rating on May 15, citing pending FDA approval of GraftAssureDx in a $2B+ market.

3 min read
JUN 17$IMDXLowSEC EDGAR 8-K

Insight Molecular Diagnostics Inc. (IMDX): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Insight Molecular Diagnostics Inc. (IMDX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001642380 0001642380 2026-06-11 2026-06-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor

3 min read
APR 28$IMDXMedStock Titan

Broadwood and Neal Bradsher hold 39.7% of Insight Molecular (IMDX) shares

Broadwood Partners, Broadwood Capital, and Neal C. Bradsher have reported a combined beneficial ownership of 12,835,134 shares, or 39.7%, of Insight Molecular Diagnostics (IMDX). This stake is based on 32,318,071 outstanding shares, adjusted to include warrants they beneficially own. The filing indicates the group intends to continuously review their investment and may engage with company management and the board to explore strategic alternatives for enhancing shareholder value.

3 min read

Related tickers

More in DIAGNOSTICS & RESEARCH